DanielH.ShevrinMD

Oncology • Evanston, IL

Genitourinary Oncology, Hospice & Palliative

Associate Professor of Medicine. U of Chicago Pritzker School of Medicine

Join to view full profile

Dr. Shevrin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shevrin's full profile

Already have an account?

Office
2650 Ridge Ave
Div. Of Hematology/Oncology
Evanston, IL 60201
Phone+1 847-570-2515

Fax+1 847-570-2336

Education & Training

University of Illinois College of Medicine at Chicago/Michael Reese HospitalFellowship, Hematology and Medical Oncology, 1981 - 1984
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1979 - 1984
University of Kansas School of MedicineClass of 1977

Certifications & Licensure

IL State Medical License 1979 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Super Doctor SuperDoctors.com

Clinical Trials

Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy Start of enrollment: 2005 Aug 01
Completed
Phase 2
Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer Start of enrollment: 2007 Mar 01
Completed
Phase 2
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
Completed
Phase 2
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
Completed
Phase 2
Afatinib in Advanced Refractory Urothelial Cancer Start of enrollment: 2017 Sep 13
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, Nabil Adra, Jingsong Zhang
Clinical Cancer Research. 2024-10-01
4 citations
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (A...
Rahul Aggarwal, Glenn Heller, David W Hillman, Han Xiao, Joel Picus
Journal of Clinical Oncology. 2024-04-01
6 citations
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Alicia K Morgans, Yu-Hui Chen, David F Jarrard, Michael Carducci, Glenn Liu
The Prostate. 2022-09-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member